India markets closed

Ligand Pharmaceuticals Incorporated (LGND)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
96.89+1.14 (+1.20%)
As of 1:41PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close95.75
Open97.55
Bid96.31 x 900
Ask96.59 x 1200
Day's range94.82 - 98.44
52-week range57.24 - 127.80
Volume162,584
Avg. volume255,651
Market cap1.558B
Beta (5Y monthly)1.45
PE ratio (TTM)N/A
EPS (TTM)-1.44
Earnings date03-Nov-2020 - 09-Nov-2020
Forward dividend & yieldN/A (N/A)
Ex-dividend date02-Jul-2010
1y target est191.80
  • LGND or ALKS: Which Is the Better Value Stock Right Now?
    Zacks

    LGND or ALKS: Which Is the Better Value Stock Right Now?

    LGND vs. ALKS: Which Stock Is the Better Value Option?

  • Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million
    Business Wire

    Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million

    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that recent new contracting with partners and investments in manufacturing capacity have contributed to its Captisol business operating at the highest levels in the history of the technology and position Captisol for major growth. Significant new clinical and regulatory developments with Evomela and Kyprolis, among other drugs, are reinforcing the role the proprietary technology serves in enabling important medicines. During 2020, Ligand has facilitated the successful installation of equipment to allow production at significantly higher levels to support anticipated demand. In addition to manufacturing at partner Hovione’s facilities in Ireland and Portugal, Ligand has now added final step processing capacity for Captisol in both the United States and England. Ligand also introduces guidance for 2021 Captisol material sales of approximately $200 million.

  • Ligand Pharmaceuticals Enters Oversold Territory
    Zacks

    Ligand Pharmaceuticals Enters Oversold Territory

    Ligand Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.